Uniting Wealth Partners LLC Decreases Position in Pfizer Inc. (NYSE:PFE)

Uniting Wealth Partners LLC decreased its position in Pfizer Inc. (NYSE:PFE) by 5.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,844 shares of the biopharmaceutical company’s stock after selling 1,495 shares during the quarter. Uniting Wealth Partners LLC’s holdings in Pfizer were worth $655,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. Rialto Wealth Management LLC purchased a new position in shares of Pfizer during the fourth quarter valued at about $26,000. Clarity Asset Management Inc. bought a new stake in Pfizer during the fourth quarter worth about $27,000. Gould Capital LLC boosted its stake in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer in the fourth quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. bought a new position in shares of Pfizer in the fourth quarter worth approximately $30,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $24.20 on Friday. The firm has a fifty day moving average price of $23.46 and a 200-day moving average price of $24.85. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The stock has a market cap of $137.56 billion, a PE ratio of 17.53, a price-to-earnings-growth ratio of 0.88 and a beta of 0.57. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.82 earnings per share. Equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.11%. Pfizer’s dividend payout ratio is 124.64%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. UBS Group upped their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. The Goldman Sachs Group reissued a “neutral” rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Citigroup reissued a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Cantor Fitzgerald assumed coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.